Mast-cell-dependent histamine release after praziquantel treatment of Schistosoma japonicum infection: implications for chemotherapy-related adverse effects.
As previously shown, the development of adverse effects in praziquantel treatment of Schistosoma japonicum infection involves host anaphylactic reactions associated with a rapid elevation of the level of plasma histamine. This study, using genetically mast-cell-deficient mice, aimed at identifying the major source of plasma histamine released after praziquantel treatment. Mast-cell-deficient mice and congenic normal mice were treated with praziquantel 8 weeks after infection with S. japonicum. In normal congenic mice, the plasma histamine level at 60 min after chemotherapy was substantially higher (mean+/-SD: 123.34+/-23.13 ng/ml) than that in mast-cell-deficient mice (7.02+/-3.48 ng/ml). These results show that mast cells play a predominant role in the rapid increase of the plasma histamine level. Despite their lack of increase in plasma histamine, mast-cell-deficient mice exhibited post-praziquantel systemic signs but not histopathologic alterations due to allergic reactions, suggesting that unidentified mechanism(s) also contribute to the development of adverse post-praziquantel effects.